Alkriz 250 mg (Capsule)
Unit Price: ৳ 750.00 (7 x 4: ৳ 21,000.00)
Strip Price: ৳ 3,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Crizotinib |
| Company | Beacon pharmaceuticals plc |
Title and Categories
- Alkriz Kinase Inhibitor
- Targeted Cancer Therapy
Indications
- Metastatic Non-Small Cell Lung Cancer (NSCLC) with ALK-positive tumors
- Metastatic NSCLC with ROS1-positive tumors
Description
- First FDA-approved biomarker-driven therapy for ALK positive and ROS1-positive metastatic NSCLC
- Only FDA-approved drug for ROS1-positive NSCLC
Mode of Action
- Inhibitor of receptor tyrosine kinases including ALK, c-Met, ROS1, RON
- Concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation
- Metabolized by CYP3A4/5
- Distribution into tissues from the plasma
Absorption
- Median time to achieve peak concentration: 4 to 6 hours
- Steady state reached within 15 days with 250 mg twice daily
- Bioavailability: 43%
- Reduced AUCinf and Cmax by approximately 14% with high-fat meal
Distribution
- Geometric mean volume of distribution: 1772 L
- Binding to human plasma proteins: 91%
- Substrate for P-glycoprotein (P-gp)
Metabolism
- Predominantly metabolized by CYP3A4/5
- Primary metabolic pathways: oxidation, O dealkylation, Phase 2 conjugation
Elimination
- Mean apparent plasma terminal half-life: 42 hours
- Recovery in feces: 63%
- Recovery in urine: 22%
- Mean apparent clearance (CL/F): 60 L/hr at steady state
Dosage & Administration
- Recommended Dose: 250 mg orally, twice daily
- Renal impairment: 250 mg orally, once daily in severe impairment
- No pediatric dose established
- Caution in hepatic impairment
Interaction
- Avoid concurrent use with strong CYP3A inhibitors and inducers
- Avoid concurrent use with CYP3A substrates with narrow therapeutic indices
Side Effects
- Common adverse reactions: vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, neuropathy
Pregnancy & Lactation
- Potential fetal harm
- Advised effective contraception for females of reproductive potential
- Not recommended during breastfeeding
Precautions & Warnings
- Periodic liver testing for hepatotoxicity
- Permanent discontinuation in ILD/Pneumonitis
- Monitoring for QT interval prolongation, bradycardia, severe visual loss
- Advisement of potential fetal risk and contraception
Storage Conditions
- Keep below 30°C temperature
- Away from light & moisture
- Keep out of the reach of children